Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma

Matteo Claudio Da Via', MD, Antonio Giovanni Solimando, MD, Andoni Garitano-Trojaola, PhD, Santiago Barrio, PhD, Nadine Rodhes, Susanne Strifler, MD, Eva Teufel, Constantin Lapa, MD, Hermann Einsele, MD, Andreas Beilhack, MD, K. Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2018-99-117203

Published: 2018

Journal Articles

Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature

Jemin Aby Jose, MD, Insija Ilyas Selene, MBBS, Mustafa Nadeem Malik, MD, Anum Qureshi, Abdul Rafae, MD, Hafiz Muhammad Fazeel, MD, Muhammad Abu Zar, MD, Ahmad Kamal, MD, Saad Ullah Malik, MD, Ceren Durer, MD, Seren Durer, MD, Faiza Jamil, MD, Madeeha Shafqat, Muhammad Usman, MD, Giyth Mithim Mahdi, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2018-99-109923

Published: 2018

Journal Articles

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, MD PhD, Zsolt Nagy, MD PhD, Szabolcs Kosztolányi, MD, Árpád Szomor, MD PhD, Tamás Schneider, MD PhD, Beáta Deák, MD PhD, Krisztina Wolf, MD, Márk Plander, MD PhD, Tamás Szendrei, MD, László Váróczy, MD PhD, Árpád Illés, MD PhD, Árpád Bátai, MD, Mónika Pető, MD, János Fábián, MD, Tamas Masszi, MD PhD, Gabor Mikala, MD PhD

Blood (2017) 130 (Supplement 1): 1865.

https://doi.org/10.1182/blood.V130.Suppl_1.1865.1865

Published: 2017

Journal Articles

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Blood (2014) 124 (21): 4752.

https://doi.org/10.1182/blood.V124.21.4752.4752

Published: 2014

Journal Articles

Initial Presentation Of Multiple Myeloma As Intraparenchymal Brain Mass

Ishan Malhotra, MBBS, Abhinav B. Chandra, MD, MSc, Yiwu Huang, MD, Ph.D.

Blood (2013) 122 (21): 5402.

https://doi.org/10.1182/blood.V122.21.5402.5402

Published: 2013

Journal Articles

Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience

Jonas Paludo, MD, Utkarsh Painuly, MD, Shaji Kumar, MD, Francis Buadi, MD, Suzanne R Hayman, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, John A. Lust, MD, PhD, David Dingli, M.D., Ph.D., Arleigh McCurdy, MD, Stephen J. Russell, MD, PhD, Nelson Leung, MD, Steven R Zeldenrust, MD, PhD, Vincent Rajkumar, MD, Morie A Gertz, M.D., Robert Kyle, MD, MACP, Prashant Kapoor, MD

Blood (2013) 122 (21): 3119.

https://doi.org/10.1182/blood.V122.21.3119.3119

Published: 2013

Journal Articles

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Christine Chen, MD, MEd, FRCPC, Ahmed M. Rabea, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Vishal Kukreti, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 3983.

https://doi.org/10.1182/blood.V118.21.3983.3983

Published: 2011

Journal Articles

Treatment of Menigeal Myelomatosis with Liposomal Cytarabine (DepoCyte ® ): A Case Report

Fabio Ardizzone, Michele Sciacca, Paola Migliora, Cristina Ravanelli, Alberto Santagostino

Blood (2008) 112 (11): 5219.

https://doi.org/10.1182/blood.V112.11.5219.5219

Published: 2008

NARROW

CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma

Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature

Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Initial Presentation Of Multiple Myeloma As Intraparenchymal Brain Mass

Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Treatment of Menigeal Myelomatosis with Liposomal Cytarabine (DepoCyte ® ): A Case Report

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only